Showing results (71-80 of 100) with videos related to

Sort By:
Pageof 10
European Heart Journal|October 12, 2017
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trialDavid Fitchett, Javed Butler, Philippe van de Borne, et al.
Diabetes, Obesity & Metabolism|February 8, 2020
Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA-REG OUTCOMESubodh Verma, Qiuhe Ji, Deepak L Bhatt, et al.
The American Journal of Cardiology|June 29, 2004
One-year outcome of patients after acute coronary syndromes (from the Canadian Acute Coronary Syndromes Registry)Andrew T Yan, Mary Tan, David Fitchett, et al.
American Heart Journal|December 18, 2007
Rationale and design of the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI)Warren J Cantor, David Fitchett, Bjug Borgundvaag, et al.
European Journal of Heart Failure|December 11, 2019
Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trialMichael Böhm, Jonathan Slawik, Martina Brueckmann, et al.
Diabetes Care|December 6, 2017
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME TrialSilvio E Inzucchi, Bernard Zinman, David Fitchett, et al.
The Canadian Journal of Cardiology|November 26, 2013
Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus updateG B John Mancini, A Yashar Tashakkor, Steven Baker, et al.
The American Journal of Cardiology|February 26, 2015
Efficacy and safety of a routine early invasive strategy in relation to time from symptom onset to fibrinolysis (a subgroup analysis of TRANSFER-AMI)Juan J Russo, Shaun G Goodman, Warren J Cantor, et al.
European Journal of Heart Failure|May 25, 2021
Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trialPierpaolo Pellicori, David Fitchett, Mikhail N Kosiborod, et al.
Stroke|April 8, 2017
Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular RiskBernard Zinman, Silvio E Inzucchi, John M Lachin, et al.
Pageof 10